Sellas Life Sciences Group (SLS) said Tuesday that group three data showed that tambiciclib topped the benchmark for median overall survival in the ongoing phase 2 relapsed/refractory acute myeloid leukemia study.
The median overall survival for all patients in the group was 8.8 months and 8.9 months for patients with AML-myelodysplasia-related changes or AML-MRC, exceeding the historical benchmark of 2.5 months, the company said.
The overall response rate in all evaluable patients was 46% in all group three patients and 67% in AML-MRC patients, surpassing the targeted 20% ORR, the company added.
The company said phase 2 trial continues in expansion groups four and five.
Shares of Sellas Life Sciences rose 5.8% in recent trading.
Price: 1.10, Change: +0.06, Percent Change: +5.77
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.